# Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).

Study · id `cardio:ct-nct06601127` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06601127](<https://clinicaltrials.gov/study/NCT06601127>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06601127

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 600 participants.

## Technical summary

Registry record NCT06601127. Randomized; quadruple masking; primary purpose treatment. Start 2025-02-21 (actual); primary completion 2026-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 600 participants (planned count; ClinicalTrials.gov record NCT06601127, source copy `cardio:ctgov-nct06601127-2025-03-07`, retrieved 2026-10-26)
- Started: 2025-02-21 (actual) (ClinicalTrials.gov record NCT06601127, source copy `cardio:ctgov-nct06601127-2025-03-07`, retrieved 2026-10-26)
- Primary completion: 2026-04-01 (anticipated) (ClinicalTrials.gov record NCT06601127, source copy `cardio:ctgov-nct06601127-2025-03-07`, retrieved 2026-10-26)
- Completion: 2026-06-01 (anticipated) (ClinicalTrials.gov record NCT06601127, source copy `cardio:ctgov-nct06601127-2025-03-07`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06601127, source copy `cardio:ctgov-nct06601127-2025-03-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06601127-2025-03-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Study of Tiprogrel in the Treatment of High-risk Patients with Acute Ischemic Cerebrovascular Events (THRIVE).
- Condition: Ischemic Stroke
- Intervention (Drug): Tiprogrel
- Intervention (Drug): Tiprogrel
- Intervention (Drug): Clopidogrel
- Lead sponsor: Tianjin Institute of Pharmaceutical Research Co., Ltd
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)

## Provenance

Content hash: 6c35edfac0ecab014102a9c8954fc0b78c8ad9dbfbdbd19f5b2447c79e41f1b8
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
